Rakovina Therapeutics Inc. (RKV:TSX.V) reported the presentation of new preclinical data from two of its lead programs at the 2026 American Association for Cancer Research Annual Meeting, held April 17 to April 22 in San Diego, California. The data were presented across two poster sessions and relate to the company's pipeline targeting DNA damage response vulnerabilities in solid tumors.
The first poster outlined results from a program developing brain-penetrant dual ATR-mTOR inhibitors designed to target PTEN-deficient cancers. According to the company, candidate compounds demonstrated equal or greater inhibition of ATR and mTOR enzymes compared to reference compounds ceralasertib and tuvusertib, along with comparable or improved selectivity against PIKK family enzymes. The candidates also showed inhibition of cell viability in D283 medulloblastoma cells and demonstrated activity in both PTEN wild-type and PTEN-deficient cancer cell lines.
The company reported that candidate compounds exhibited metabolic stability after 45 minutes of incubation with human liver microsomes. Pharmacokinetic profiling in mice showed measurable central nervous system penetrance, with brain-to-plasma ratios consistent with AI predictions. In a subcutaneous prostate tumor model, a prototype lead candidate prolonged tumor doubling time compared to a vehicle control, with potency comparable to ceralasertib and reduced tolerability impacts, including less weight loss and no hematological toxicity observed at terminal analysis. The company stated that optimization of candidate inhibitors is ongoing.
The second poster presented data on a lipid nanoparticle formulation of the bifunctional PARP and HDAC inhibitor kt-3283. The company reported that the formulation, developed using an AI platform, demonstrated successful nanoparticle assembly with uniform particle size, stable colloidal behavior, and structured surface characteristics. These features were described as supporting further biological evaluation. The formulation was developed to address previously identified limitations in bioavailability and metabolic stability.
Rakovina stated that the next steps for the KT-3283 program include in vitro and in vivo characterization to confirm enzyme activity, determine ADME properties, and evaluate efficacy in tumor models.
"Presenting at AACR is a meaningful milestone for our team, and these results represent a genuine step forward for both programs," said Kim Oishi, Chief Executive Officer of Rakovina Therapeutics, in a company news release. "The in vivo efficacy data for our ATR-mTOR inhibitor are particularly encouraging."
Dr. Mads Daugaard, President and Chief Scientific Officer, added that "our candidate inhibitors are tracking closely with the AI predictions for potency, selectivity, and CNS penetrance and our in vivo results give confidence in the direction of this program."
The company stated that the data inform the next phase of preclinical development, with continued optimization for the ATR-mTOR program and further biological characterization planned for the kt-3283 formulation.
Advancement of Preclinical Programs and Development Milestones
According to the company's investor presentation, the ATR-mTOR inhibitor program included ongoing collaboration with Variational AI for optimization of initial lead compounds during 2026. The company reported that this work includes chemical synthesis and evaluation in its laboratories, along with continued data presentations at peer-reviewed scientific meetings. The presentation also noted that discussions with potential partner organizations are ongoing.
The same presentation outlined 2026 milestones for the ATR-mTOR program, including the presentation of in vivo model data at peer-reviewed meetings and the delivery of lead-optimization results from the expanded collaboration with Variational AI.
For the PARP1 inhibitor program, the company stated that select compounds identified through in silico screening have been synthesized and are undergoing evaluation. The investor presentation indicated that PARP activity and ADME data from these compounds will be used to further train the AI model for refinement and lead candidate selection. Planned 2026 milestones include receipt of output from further AI modeling and presentation of lead compound data at peer-reviewed scientific meetings.
Streetwise Ownership Overview*
Rakovina Therapeutics Inc. (RKV:TSX.V)
For the kt-3283 PARP/HDAC inhibitor program, the company reported that it has established a joint venture with NanoPalm Ltd. to develop a formulation aimed at improving in vivo delivery. The presentation noted that the collaboration combines the company's AI-enabled drug discovery platform with NanoPalm's lipid nanoparticle delivery system. The company also stated that the joint venture will seek non-dilutive funding.
Additional 2026 milestones for the KT-3283 program include pursuing partnerships with companies developing antibody drug conjugate payloads and presenting nano-lipid formulation data at peer-reviewed meetings.
Ownership and Share Structure1
Edison Oncology holds approximately 12% of Rakovina Therapeutics. Management and reporting insiders account for about 4% ownership, with the remainder held by a combination of institutional, retail, and other investors, as previously disclosed in company materials.
Rakovina completed a 10-to-1 share consolidation in June 2025, with shareholders receiving one post-consolidation common share for every ten previously held.
As of April 2026, the company has approximately 21.15 million shares outstanding. Market capitalization is approximately CA$2.1 million to CA$2.7 million based on recent trading levels.
Over the past 52 weeks, Rakovina Therapeutics' share price has ranged between approximately CA$0.085 and CA$1.30.
| Want to be the first to know about interesting Healthcare Services and Biotechnology / Pharmaceuticals investment ideas? Sign up to receive the FREE Streetwise Reports' newsletter. | Subscribe |
Important Disclosures:
- Rakovina Therapeutics Inc. has a consulting relationship with Street Smart an affiliate of Streetwise Reports. Street Smart Clients pay a monthly consulting fee between US$8,000 and US$20,000.
- As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of Rakovina Therapeutics Inc.
- James Guttman wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
- This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
- This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
For additional disclosures, please click here.
1. Ownership and Share Structure Information
The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.
